newscontact us

Cesca Therapeutics and Cook Medical Enter Supply Agreement for a Phase 1b Clinical Trial

RANCHO CORDOVA, Calif. and WEST LAFAYETTE, Ind., Feb. 24, 2014 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., announced today that they have entered a supply agreement with Cook Medical.

“We have found the ideal partner in Cook Medical to supply catheters, angioplasty balloons and other interventional products for the AMIRST Phase 1b trial,” said Matthew Plavan, CEO, Cesca Therapeutics.

Under the terms of the agreement, Cook Medical has been chosen as the supplier for select delivery device products for the AMIRST (Acute Myocardial Infarction Rapid Stem cell Therapy) Phase Ib trial set to begin later this calendar year. The clinical trial is for targeted marketing approval in the United States, European Union Community and India.

Ken Harris, President of Cesca Therapeutics commented, “We look forward to Cook Medical’s product contribution to the AMIRST trial, and know that their expertise in medical devices will support our success and advancing the field of regenerative and cellular medicine.”

022414 Cook Agreement Final